Minimising the risks of allergen-specific injection immunotherapy.

@article{Malling2000MinimisingTR,
  title={Minimising the risks of allergen-specific injection immunotherapy.},
  author={Hans-J\orgen Malling},
  journal={Drug safety},
  year={2000},
  volume={23 4},
  pages={323-32}
}
The clinical advantages of allergen-specific immunotherapy are counterbalanced by the risk of inducing systemic adverse effects. Although the frequency of life-threatening systemic reactions is low, the treatment carries a risk of inducing anaphylactic reactions. A fundamental point in risk assessment is to use a clinically meaningful and internationally accepted grading system for reactions. Of importance in minimising the risk of systemic adverse effects is the identification of at-risk… CONTINUE READING